Friday, 17 Nov 2017

You are here

1 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections - HBV, shingles and mortality of septic arthritis.

Please donate something/anything to American Red Cross to help victims of Hurricaine Harvey. I did! Every bit helps https://t.co/CmlDWfRX6R  or text HARVEY to 90999 to donate $10.

Watch for RheumNow’s novel new coverage of the 2017 ACR meeting from San Diego! We'll have a microsite dedicated to the meeting, and multiple RN faculty will report on site, providing pics, tweets, articles and videos from leading rheumatologists. 

  1. 25 studies shows low risk of HBV reactivation (1.6%) w/ resolved HBV - not changed by TNFi, other biologics, DMARDs https://t.co/wzjikRHPFh  
  2. 1667 geriatric pts w/ Septic arthritis matched 1:10 w/o; those w/ Septic arthritis had 50-100% increase mortality https://t.co/LcMpdKT6pI
  3. RT @NYTHealth: FDA announces crackdown on "unscrupulous" stem cell clinics. https://t.co/uQajkkZF5x
  4. Severe (ocular) Behcets study: ~half respond to TNF inhib but only half these stay in remission w/ TNFi withdrawal https://t.co/a2oGZADlle
  5. Epidemiology of SLE varied but incidence appears to be increasing. Highest frequencies in AA, N America (23/100K-PY); lowest in Africa, Ukraine, N. Australia https://t.co/jK9tJ2Ybqy
  6. Untreated Sleep apnea increases free fatty acids, glucose, cortisol and blood pressure during sleep. https://buff.ly/2eHGiay
  7. FDA approves 1st gene therapy - CAR T-cell therapy approved B-cell acute lymphoblastic leukemia https://t.co/wPNHbQIhwx
  8.  FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome - https://t.co/hGJcWyZEy5
  9. Turnabout for Baricitinib  
  10. Another Adalimumab Biosimilar Approved 
  11. Canakinumab Reduces CV Outcomes in High Risk Patients  
  12. Canakinumab Patients have Lower Risk of Lung Cancer
  13. Shingles Vaccine Studies in A&R  
  14. Therapeutic Update:  See what Drs. Mease, Gibofsky, Cush have to say about FDA hearing on Tofacitinib for Psoriatic Arthritis 
  15. The job is not you, nor is your income, car or good looks. You are your principles and what you do when those principles are needed.  Listen to this podcast by Malcolm Gladwell

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 17 November 2017

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Podcast of ACR17 - Day 4

Care to learn what you missed at last weeks ACR 2017 meeting in San Diego?  Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers.  Another good way to learn from RheumNow.

The ACR17 RheumNow Week in Review - 10 November 2017

This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr. Jack Cush reviews lupus and the microbiome, daily podcasts, pregnancy and lactation, osteoporosis drug holidays and screening for pulmonary hypertension.

Many thanks to the RheumNow Faculty for their work and expertise!

Podcast of ACR 17 - Day 3

Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !

ACR 2017 - Day 3 and 4 Highlights

Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report).  Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.